Comprehensive analysis of clinical indications and viral strain variants among patients infected with SARS-CoV-2 in Inner Mongolia, China.

Since the first appearance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019, the virus is still evolving and mutating until now. In this study, we collected 6 throat swabs from patients who diagnosed with COVID-19 in Inner Mongolia, China, to understand the entry of multiple SARS-CoV-2 variants into Inner Mongolia and analyze the relationships between variants and clinical features observed in infected patients. In addition, we performed a combined analysis of clinical parameters associated with SARS-CoV-2 variants of interest, pedigree analysis, and detection of single-nucleotide polymorphisms. Our results showed that the clinical symptoms were generally mild although some patients demonstrated some degree of liver function abnormalities, and the SARS-CoV-2 strain was related to the Delta variant (B.1.617.2), AY.122 lineage. The epidemiological investigations and clinical manifestations confirmed that the variant exhibits strong transmission, a high viral load, and moderate clinical symptoms. SARS-CoV-2 has undergone extensive mutations in various hosts and countries. Timely monitoring of virus mutation can help to monitor the spread of infection and characterize the diversity of genomic variants, thus limiting future waves of SARS-CoV-2 infection.

LncRNA PCED1B-AS1 Upregulation in Hepatocellular Carcinoma and Regulation of the miR-10a/BCL6 Axis to Promote Cell Proliferation.

Long noncoding RNA (lncRNA) PCED1B-AS1 has been characterized as an oncogene in glioma, but its role in hepatocellular carcinoma (HCC) is unknown. We explored the involvement of PCED1B-AS1 in HCC. Its expression in paired HCC and nontumor tissues from 62 HCC patients was determined by qRT-PCR. Correlations of PCED1B-AS1 with miR-10a and BCL6 were analyzed by Pearson's correlation coefficient. The patients were followed up for 5 years to analyze the prognostic value of PCED1B-AS1 for HCC. Interactions among PCED1B-AS1, miR-10a, and BCL6 were detected by overexpression experiments. Cell proliferation was analyzed by CCK-8 assay. We found the following. PCED1B-AS1 is upregulated in HCC, and its upregulation correlates with poor survival. Across HCC tissues, PCED1B-AS1 expression inversely correlates with miR-10a but positively correlates with BCL6. In HCC cells, overexpression of PCED1B-AS1 decreases miR-10a expression and increases BCL6 expression. Moreover, PCED1B-AS1 overexpression reduces the inhibitory effects of miR-10a overexpression on BCL6 expression and cell proliferation. PCED1B-AS1 is upregulated in HCC and regulates the miR-10a/BCL6 axis to promote cell proliferation.

Knockdown of Rab7a suppresses the proliferation, migration, and xenograft tumor growth of breast cancer cells.

Breast cancer is a common invasive cancer in women. Ras-related protein Rab-7a (Rab7a) is involved in late endocytic trafficking, while its role in breast cancer is largely unclear. In the present study, we investigated the role of Rab7a in breast cancer. Comparing with adjacent breast tissues, Rab7a expression was increased in breast cancer tissues. Using lentivirus-mediated knockdown strategy, we found that Rab7a silencing inhibited the proliferation and colony formation of MDA-MB-231 cells. Apoptosis and G2 cell cycle arrest were induced in Rab7a knockdown. By contrast, Rab7a suppressed the apoptosis and promoted proliferation and colony formation of MCF-7 cells. The migration of MDA-MB-231 cells was suppressed by Rab7a knockdown. In vivo, depletion of Rab7a inhibited the xenograft tumor development of MDA-MB-231 cells. Altogether, our results highlight the novel function of Rab7a in the proliferation, invasion, and xenograft tumor development of breast cancer cells.

[Expression level of p53 in Tumor Tissue of Patients with Acute Leukemia and Its Clinical Significance].

OBJECTIVE: To study the expression level of p53 in tumor tissue of patients with acute leukemia (AL) and its clinical significance. METHODS: From April 2013 to April 2015, 80 patients with AL in our hospital were chosen as leukemia group, at the same time, 50 patients with non-hematologic diseases were chosen as control group. All the patients were detected by bone marrow smear mean and p53 staining. The positive rate of p53 and staining score were compared between 2 groups. The clinical data of leukemia group were collected, and the correlation of clinical features with p53 expression was analyzed. RESULTS: In the control group, the positive rate of p53 was 6.00%, the staining score was (0.2 ± 0.1); in the leukemia group, the positive rate of p53 was 73.75%, the staining score was (1.9 ± 0.4), the difference was statistically significant (P < 0.05). The expression of p53 significantly correlated with the blood routine indicators, clinical manifestation, multiple infiltration and curative effects (P < 0.05), and the p53 expression not correlated statistically with the sex, age, anamnesis, family history (P > 0.05). CONCLUSION: Compared with the patients with non-hematologic diseases, the expression level of p53 in the AL patients increases significantly, the p53 expression correlates significantly with the blood routine indicators, clinical manifestation and curative effect of the patients.